Desvenlafaxine Tablet, Extended Release
Product Images NDC 51991-311

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 51991-311). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Breckenridge Pharmaceutical, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine 100

Label for Desvenlafaxine Extended-Release Tablets, 100 mg strength, oral dosage form, with 30 tablets per unit. Distributed by Breckenridge Pharmaceutical, Inc. The label includes storage instructions, a barcode, and regulatory information, including NDC 51991-312-33.*

FDA Label Image

Desvenlafaxine 25

Label for Desvenlafaxine Extended-Release Tablet 25 mg by Breckenridge Pharmaceutical, Inc. The film-coated tablet contains 38 mg desvenlafaxine succinate equivalent to 25 mg desvenlafaxine. The package contains 30 tablets with a unit of use. Storage instructions and distributor/manufacturer details are included. Rx only.*

FDA Label Image

Desvenlafaxine 50

Desvenlafaxine Extended-Release Tablets 50 mg oral tablets packaging label. The label shows the drug name, strength, dosage form, NDC number 51991-311-33, quantity of 30 tablets, and is marked Rx Only. Distributed by Breckenridge Pharmaceutical, Inc and manufactured by Alembic Pharmaceuticals Limited. Instructions for storage and pharmacist dispensing are included, along with barcodes and a GTIN.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A forest plot showing geometric mean ratios with 90% confidence intervals for Desvenlafaxine pharmacokinetics (Cmax and AUC) across different populations. It compares renal impairment levels (mild to ESRD), hepatic impairment (mild to severe), and population subgroups by gender and age groups (65-75 years, >75 years), illustrating changes relative to reference values.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A chart depicting the geometric mean ratio with 90% confidence intervals for the pharmacokinetic parameters Cmax and AUC of Desvenlafaxine in the presence of the CYP3A4 inhibitor ketoconazole. The x-axis represents change relative to reference, ranging from 0.5 to 2.0, showing values greater than 1 for both parameters.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A geometric mean ratio chart with 90% confidence intervals comparing pharmacokinetic parameters Cmax and AUC for desvenlafaxine at various doses (50 mg, 100 mg, 400 mg) against interacting drugs desipramine, midazolam, tamoxifen, and aripiprazole. The graph shows changes relative to reference values for these drug interactions with corresponding confidence intervals.*

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

A Kaplan-Meier plot depicting estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares Desvenlafaxine Extended-Release Tablets 50 mg versus Placebo, showing the relapse rate trends for both groups up to approximately 180 days.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

A survival curve chart illustrating the estimated proportion of patients with relapse (%) over time (days from randomization). The chart compares relapse rates between patients taking Desvenlafaxine Extended-Release Tablets and those given a placebo, with the x-axis representing days to relapse and the y-axis showing the proportion of patients relapsing.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

Chemical structure diagram of Desvenlafaxine Succinate showing molecular components and bonds, including hydroxyl groups, carboxyl groups, and associated molecular features.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.